|drug2999||Saliva sample Wiki||1.00|
|drug991||Data collection Wiki||0.45|
|drug2152||Nasopharyngeal swab Wiki||0.38|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
The purpose of this study is to find out if estrogen, a female sex hormone, given as a patch placed on skin of COVID19 positive or presumptive positive patients for 7 days can reduce the severity of COVID19 symptoms compared to regular care. This study has two study groups. One group will receive the study drug, a single-use Climara 25cm2 estrogen patch. The other group will receive standard of care. Participants will be asked questions about their symptoms for up 6 times in up to 45 days.
Description: Admission to hospital due to COVID-19 symptomsMeasure: Rate of Hospitalization Time: 30 days
Description: Occurrence of admission to ICU due to COVID-19 symptomsMeasure: Rate of Transfer to Intensive Care Unit Time: 30 days
Description: Occurrence of intubationMeasure: Rate of Intubation Time: 30 days
Description: Occurrence of death from COVID-19Measure: Rate of Death Time: 30 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports